Abstract
We conducted a double-blind trial in which 653 HIV-infected adults who had not received
gov
Herd protection was probably achieved in some countries and a decrease in the HPV prevalence among both vaccinated and non-vaccinated women was observed [ 27 , 109 , 116 ]
Background Cervical cancer is the most common female malignancy in the developing nations and
On the one hand, immunotherapy can be used as a booster in the form of checkpoint inhibitors or vaccines to trigger a patient’s immune system
Human papillomavirus (HPV) infection induces almost all cervical cancers and it is related to about 90% of anal cancer, 50% of penile cancer, 70% of vagina cancer and 20-60% of oropharyngeal cancer, among which cervical cancer is one of the most common cancers that threaten women’s health, besides it is the
S
Clinical and basic diagnostic tests were done at KNH while scientific aspects of Lopinavir-ritonavir treatment was stopped early in 13 patients (13
Cao et al
Most recently, it has been suggested that the protease inhibitor lopinavir could become a new form of treatment for cervical cancer
Lopinavir in combination with ritonavir is approved for the treatment of HIV and has recently been subject to a clinical trial in severe COVID-19
The initial vaccination was administered at the baseline We would like to show you a description here but the site won’t allow us
We identified only one randomised clinical trial that compared lopinavir–ritonavir with usual care in patients with COVID-19